non-small cell lung cancer

Lilly’s Cyramza closer to first-line lung cancer use after ODAC verdict
Lilly’s Cyramza closer to first-line lung cancer use after ODAC verdict
Pharmaforum
Eli Lilly
Cyramza
non-small cell lung cancer
FDA
advisory panels
Flag link:
Takeda’s ALUNBRIG gets FDA priority review for expanded indication in NSCLC
Takeda’s ALUNBRIG gets FDA priority review for expanded indication in NSCLC
Pharmaceutical Business Review
Takeda
Alunbrig
brigatinib
FDA
priority review
non-small cell lung cancer
Flag link:
FDA Grants Priority Review to Roche's Lung Cancer Drug Tecentriq
FDA Grants Priority Review to Roche's Lung Cancer Drug Tecentriq
Motley Fool
Roche
FDA
priority review
Tecentriq
non-squamous non-small cell lung cancer
non-small cell lung cancer
Flag link:
Novartis nabs priority review for a blockbuster-to-be aimed at NSCLC niche — delighting Incyte execs
Novartis nabs priority review for a blockbuster-to-be aimed at NSCLC niche — delighting Incyte execs
Endpoints
Incyte
Novartis
FDA
capmatinib
prioirty review
non-small cell lung cancer
Flag link:
Bristol-Myers Withdraws European Application for Lung Cancer Combo
Bristol-Myers Withdraws European Application for Lung Cancer Combo
Motley Fool
Bristol-Myers Squibb
Europe
Opdivo
Yervoy
non-small cell lung cancer
Flag link:
Racing Blueprint, Lilly drug gets priority review for RET hopeful
Racing Blueprint, Lilly drug gets priority review for RET hopeful
Fierce Biotech
Eli Lilly
FDA
Blueprint Medicines
selpercatinib
LOXO-292
thyroid cancer
non-small cell lung cancer
Flag link:
BeiGene’s Tislelizumab Could Challenge Merck’s Keytruda in the Checkpoint Inhibitor Market
BeiGene’s Tislelizumab Could Challenge Merck’s Keytruda in the Checkpoint Inhibitor Market
BioSpace
BeiGene
tiselizumab
non-small cell lung cancer
Merck
Keytruda
Flag link:
Spectrum Pharma Shares Slump After Lung-Cancer Drug Doesn't Meet Phase II Endpoint
Spectrum Pharma Shares Slump After Lung-Cancer Drug Doesn't Meet Phase II Endpoint
TheStreet.com
Spectrum Pharma
lung cancer
clinical trials
poziotinib
non-small cell lung cancer
Flag link:
ESMO I-O: Roche silences Tecentriq doubters with latest lung cancer analysis
ESMO I-O: Roche silences Tecentriq doubters with latest lung cancer analysis
Fierce Pharma
ESMO
Roche
Tecentriq
non-small cell lung cancer
Flag link:
AZ’s Imfinzi approved in early lung cancer in China
AZ’s Imfinzi approved in early lung cancer in China
Pharmaforum
China
AstraZeneca
Imfinizi
non-small cell lung cancer
Flag link:
Merck's Keytruda lung cancer sales may face new pressure, but investors shouldn't sweat it: analyst
Merck's Keytruda lung cancer sales may face new pressure, but investors shouldn't sweat it: analyst
Fierce Pharma
Merck
Keytruda
non-small cell lung cancer
Flag link:
AstraZeneca, on BMS' heels, scores lung cancer win with Imfinzi combos
AstraZeneca, on BMS' heels, scores lung cancer win with Imfinzi combos
Fierce Pharma
AstraZeneca
Imfinizi
non-small cell lung cancer
Flag link:
Bristol-Myers makes Opdivo pitch for frontline lung cancer with open label PhIII study
Bristol-Myers makes Opdivo pitch for frontline lung cancer with open label PhIII study
Endpoints
Bristol-Myers Squibb
Opdivo
non-small cell lung cancer
advanced non-small cell lung cancer
clinical trials
Flag link:
Merck’s KEYTRUDA approved as monotherapy in China for first-line treatment of certain patients with advanced NSCLC
Merck’s KEYTRUDA approved as monotherapy in China for first-line treatment of certain patients with advanced NSCLC
Pharmaceutical Business Review
Merck
Keytruda
China
non-small cell lung cancer
Flag link:
Samsung Bioepis announces phase 3 results of SB8, Bevacizumab biosimilar candidate, at ESMO 2019 Congress
Samsung Bioepis announces phase 3 results of SB8, Bevacizumab biosimilar candidate, at ESMO 2019 Congress
Pharmaceutical Business Review
ESMO
Samsung Bioepis
clinical trials
SB8
biosimilars
bevacizumab
non-small cell lung cancer
Flag link:
OncoCyte Acquires Razor Genomics to Improve Management of Early-Stage Lung Cancer
OncoCyte Acquires Razor Genomics to Improve Management of Early-Stage Lung Cancer
BioSpace
OncoCyte
Razor Genomics
diagnostics
M&A
non-small cell lung cancer
Flag link:
Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer study
Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer study
Pharmaceutical Business Review
Roche
Tecentriq
clinical trials
non-small cell lung cancer
Flag link:
Merck KGaA nabs FDA “Breakthrough” tag for MET-targeting lung cancer drug
Merck KGaA nabs FDA “Breakthrough” tag for MET-targeting lung cancer drug
Pharmaforum
FDA
Merck KGaA
MET
lung cancer
tepotinib
non-small cell lung cancer
Flag link:
WCLC: Merck's Keytruda dispels 'urban legend' with latest lung cancer survival win
WCLC: Merck's Keytruda dispels 'urban legend' with latest lung cancer survival win
Fierce Pharma
Merck
Keytruda
non-small cell lung cancer
WCLC
Flag link:
Lilly's RET drug, nabbed in Loxo buyout, hits 68% ORR in lung cancer
Lilly's RET drug, nabbed in Loxo buyout, hits 68% ORR in lung cancer
Fierce Biotech
Eli Lilly
Loxo Oncology
LOXO-292
non-small cell lung cancer
Flag link:

Pages